DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, Geeta George, Kebede Begna, Susan Schwager, Daniel Van Dyke, Curtis Hanson, Wenting Wu, Animesh D Pardanani, Francisco Cervantes, Francesco Passamonti, Ayalew Tefferi

Research output: Contribution to journalArticle

503 Citations (Scopus)

Abstract

Purpose: The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower than 10 g/dL, leukocytes higher than 25 × 109/L, circulating blasts ≥ 1%, and constitutional symptoms. The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status. Patients and Methods: Mayo Clinic databases for PMF were used to identify patients with available bone marrow histologic and cytogenetic information. Results: Seven hundred ninety-three consecutive patients were selected and divided into two groups based on whether or not their referral occurred within (n = 428; training set) or after (n = 365; test set) 1 year of diagnosis. Multivariable analysis identified DIPSS, unfavorable karyotype, platelets lower than 100 ± 109/L, and transfusion need as independent predictors of inferior survival. Hazard ratio (HR) -weighted adverse points were assigned to these variables to develop a composite prognostic model using the training set. The model was subsequently validated in the test set, and its application to all 793 patients resulted in median survivals of 185, 78, 35, and 16 months for low, intermediate-1 (HR, 2.2; 95% CI, 1.4 to 3.6), intermediate-2 (HR, 4.9; 95% CI, 3.2 to 7.7), and high-risk groups (HR, 10.7; 95% CI, 6.8 to 16.9), respectively (P < .001). Leukemia-free survival was predicted by the presence of thrombocytopenia or unfavorable karyotype (10-year risk of 31% v 12%; HR, 3.3; 95% CI, 1.9 to 5.6). Conclusion: DIPSS plus effectively combines prognostic information from DIPSS, karyotype, platelet count, and transfusion status to predict overall survival in PMF. In addition, unfavorable karyotype or thrombocytopenia predicts inferior leukemia-free survival.

Original languageEnglish (US)
Pages (from-to)392-397
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number4
DOIs
StatePublished - Feb 1 2011

Fingerprint

Platelet Transfusion
Primary Myelofibrosis
Platelet Count
Karyotype
Survival
Thrombocytopenia
Leukemia
Cytogenetics
Hemoglobins
Leukocytes
Referral and Consultation
Blood Platelets
Bone Marrow
Databases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

DIPSS plus : A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. / Gangat, Naseema; Caramazza, Domenica; Vaidya, Rakhee; George, Geeta; Begna, Kebede; Schwager, Susan; Van Dyke, Daniel; Hanson, Curtis; Wu, Wenting; Pardanani, Animesh D; Cervantes, Francisco; Passamonti, Francesco; Tefferi, Ayalew.

In: Journal of Clinical Oncology, Vol. 29, No. 4, 01.02.2011, p. 392-397.

Research output: Contribution to journalArticle

Gangat, Naseema ; Caramazza, Domenica ; Vaidya, Rakhee ; George, Geeta ; Begna, Kebede ; Schwager, Susan ; Van Dyke, Daniel ; Hanson, Curtis ; Wu, Wenting ; Pardanani, Animesh D ; Cervantes, Francisco ; Passamonti, Francesco ; Tefferi, Ayalew. / DIPSS plus : A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 4. pp. 392-397.
@article{013597873aee457eae1ed3f587e21c5f,
title = "DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status",
abstract = "Purpose: The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower than 10 g/dL, leukocytes higher than 25 × 109/L, circulating blasts ≥ 1{\%}, and constitutional symptoms. The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status. Patients and Methods: Mayo Clinic databases for PMF were used to identify patients with available bone marrow histologic and cytogenetic information. Results: Seven hundred ninety-three consecutive patients were selected and divided into two groups based on whether or not their referral occurred within (n = 428; training set) or after (n = 365; test set) 1 year of diagnosis. Multivariable analysis identified DIPSS, unfavorable karyotype, platelets lower than 100 ± 109/L, and transfusion need as independent predictors of inferior survival. Hazard ratio (HR) -weighted adverse points were assigned to these variables to develop a composite prognostic model using the training set. The model was subsequently validated in the test set, and its application to all 793 patients resulted in median survivals of 185, 78, 35, and 16 months for low, intermediate-1 (HR, 2.2; 95{\%} CI, 1.4 to 3.6), intermediate-2 (HR, 4.9; 95{\%} CI, 3.2 to 7.7), and high-risk groups (HR, 10.7; 95{\%} CI, 6.8 to 16.9), respectively (P < .001). Leukemia-free survival was predicted by the presence of thrombocytopenia or unfavorable karyotype (10-year risk of 31{\%} v 12{\%}; HR, 3.3; 95{\%} CI, 1.9 to 5.6). Conclusion: DIPSS plus effectively combines prognostic information from DIPSS, karyotype, platelet count, and transfusion status to predict overall survival in PMF. In addition, unfavorable karyotype or thrombocytopenia predicts inferior leukemia-free survival.",
author = "Naseema Gangat and Domenica Caramazza and Rakhee Vaidya and Geeta George and Kebede Begna and Susan Schwager and {Van Dyke}, Daniel and Curtis Hanson and Wenting Wu and Pardanani, {Animesh D} and Francisco Cervantes and Francesco Passamonti and Ayalew Tefferi",
year = "2011",
month = "2",
day = "1",
doi = "10.1200/JCO.2010.32.2446",
language = "English (US)",
volume = "29",
pages = "392--397",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - DIPSS plus

T2 - A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

AU - Gangat, Naseema

AU - Caramazza, Domenica

AU - Vaidya, Rakhee

AU - George, Geeta

AU - Begna, Kebede

AU - Schwager, Susan

AU - Van Dyke, Daniel

AU - Hanson, Curtis

AU - Wu, Wenting

AU - Pardanani, Animesh D

AU - Cervantes, Francisco

AU - Passamonti, Francesco

AU - Tefferi, Ayalew

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Purpose: The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower than 10 g/dL, leukocytes higher than 25 × 109/L, circulating blasts ≥ 1%, and constitutional symptoms. The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status. Patients and Methods: Mayo Clinic databases for PMF were used to identify patients with available bone marrow histologic and cytogenetic information. Results: Seven hundred ninety-three consecutive patients were selected and divided into two groups based on whether or not their referral occurred within (n = 428; training set) or after (n = 365; test set) 1 year of diagnosis. Multivariable analysis identified DIPSS, unfavorable karyotype, platelets lower than 100 ± 109/L, and transfusion need as independent predictors of inferior survival. Hazard ratio (HR) -weighted adverse points were assigned to these variables to develop a composite prognostic model using the training set. The model was subsequently validated in the test set, and its application to all 793 patients resulted in median survivals of 185, 78, 35, and 16 months for low, intermediate-1 (HR, 2.2; 95% CI, 1.4 to 3.6), intermediate-2 (HR, 4.9; 95% CI, 3.2 to 7.7), and high-risk groups (HR, 10.7; 95% CI, 6.8 to 16.9), respectively (P < .001). Leukemia-free survival was predicted by the presence of thrombocytopenia or unfavorable karyotype (10-year risk of 31% v 12%; HR, 3.3; 95% CI, 1.9 to 5.6). Conclusion: DIPSS plus effectively combines prognostic information from DIPSS, karyotype, platelet count, and transfusion status to predict overall survival in PMF. In addition, unfavorable karyotype or thrombocytopenia predicts inferior leukemia-free survival.

AB - Purpose: The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower than 10 g/dL, leukocytes higher than 25 × 109/L, circulating blasts ≥ 1%, and constitutional symptoms. The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status. Patients and Methods: Mayo Clinic databases for PMF were used to identify patients with available bone marrow histologic and cytogenetic information. Results: Seven hundred ninety-three consecutive patients were selected and divided into two groups based on whether or not their referral occurred within (n = 428; training set) or after (n = 365; test set) 1 year of diagnosis. Multivariable analysis identified DIPSS, unfavorable karyotype, platelets lower than 100 ± 109/L, and transfusion need as independent predictors of inferior survival. Hazard ratio (HR) -weighted adverse points were assigned to these variables to develop a composite prognostic model using the training set. The model was subsequently validated in the test set, and its application to all 793 patients resulted in median survivals of 185, 78, 35, and 16 months for low, intermediate-1 (HR, 2.2; 95% CI, 1.4 to 3.6), intermediate-2 (HR, 4.9; 95% CI, 3.2 to 7.7), and high-risk groups (HR, 10.7; 95% CI, 6.8 to 16.9), respectively (P < .001). Leukemia-free survival was predicted by the presence of thrombocytopenia or unfavorable karyotype (10-year risk of 31% v 12%; HR, 3.3; 95% CI, 1.9 to 5.6). Conclusion: DIPSS plus effectively combines prognostic information from DIPSS, karyotype, platelet count, and transfusion status to predict overall survival in PMF. In addition, unfavorable karyotype or thrombocytopenia predicts inferior leukemia-free survival.

UR - http://www.scopus.com/inward/record.url?scp=79952087335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952087335&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.32.2446

DO - 10.1200/JCO.2010.32.2446

M3 - Article

C2 - 21149668

AN - SCOPUS:79952087335

VL - 29

SP - 392

EP - 397

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -